XNAS · Healthcare · Biotechnology
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | Q1 2026 | — | -3.32 | — | $0 | — | +2.57% | -20.94% | +54.46% |
| 2026-01-20 | Q4 2025 | — | -4.75 | — | $0 | — | -5.30% | +1.52% | -53.03% |
| 2025-09-11 |
| Q3 2025 |
| — |
| -0.25 |
| — |
| $0 |
| — |
| — |
| — |
| — |
| 2025-03-13 | Q1 2025 | — | -0.24 | — | $0 | — | +0.89% | +3.54% | -18.22% |
| 2025-01-22 | Q4 2024 | — | -0.11 | — | $0 | — | +2.76% | -5.52% | -11.03% |
| 2024-09-16 | Q3 2024 | — | -0.59 | — | $0 | — | +0.75% | -9.02% | +7.52% |
| 2024-06-13 | Q2 2024 | — | -0.28 | — | $0 | — | +2.78% | +18.52% | +105.56% |
Showing last 7 quarters.